Setting new standards in cardiac care technology

AppSens, a Lillesand-based company, has developed a groundbreaking sensor capable of detecting atrial fibrillation and other arrhythmias, which can serve as early indicators of stroke or heart failure. AppSens' technology has the potential to facilitate timely preventive measures, ultimately saving lives.  

What sets AppSens' technology apart is its remarkable simplicity and real-time heart rhythm analysis. The wireless sensor, when applied, seamlessly connects to an analysis service via a mobile phone. Consequently, both patients and medical professionals can monitor measurements. Moreover, the system continuously analyzes heart data, detecting irregularities through advanced algorithms, cloud-based data processing, and artificial intelligence.  

"AppSens' dedication to combining advanced algorithms, cloud-based data processing, and artificial intelligence in their ECG247 technology is commendable. Their commitment to making heart health monitoring more accessible and effective is truly inspiring", Andreas Eskeland, investment partner in Skagerak Capital, says.

The sensor, affixed to an adhesive patch, can perform analyses for up to two weeks. In contrast, other technologies are often confined to hospital use, limited to shorter periods, or less comfortable and more complex to set up. The investment teams at Skagerak Capital and Agder Seed have personally tested the solution and can attest to its user-friendliness and comfort even over extended periods.

AppSens' technology is currently in use at hospitals, heart specialist clinics, and general practitioners' offices in multiple countries, and it is also available through Norwegian online pharmacies. In recent times, international interest in the technology has surged. In late 2022, AppSens was selected to participate in Norscreen, a heart study at Oslo University Hospital with a grant of 20 million Norwegian kroner.

"AppSens and ECG247 are promising medtech companies with significant international potential," says investment partner Andreas Eskeland. With over 15,000 completed EKG tests and several hundred clinic and hospital clients, the company is well-positioned for substantial growth in the coming years.

Commercializing health technology can often be a time-consuming process due to the need for certifications and establishing trust among distributors, medical institutions, and patients. However, AppSens is now in an excellent position for significant growth. The solution's ease of use and affordability make it a competitive alternative to existing technologies, encouraging more at-risk individuals to undergo atrial fibrillation testing. The analysis platform is also user-friendly for medical professionals, enabling efficient analysis and diagnosis.

"The ease of use and affordability of AppSens' solution make it a game-changer in the field of EKG procedures. It has the potential to significantly impact the lives of individuals at risk of heart-related issues."

Read more here: